Home
Search
Toolkit for Advocates

Toolkit for Advocates

We’ve made it easier for you to access information and share content about biotechnology and how it improves our daily lives, from prescription medications and a resilient food supply to renewable energy and sustainable bioprocessing materials. The information you discover can easily be shared on Twitter, Facebook and LinkedIn.

  • Show All
Results
  • Show All
PDF
DSH Hospital Abuse the 340B Drug Pricing Program
FLIP
Many hospitals in the 340B Program are exploiting lax eligibility criteria and program guardrails to profit from the substantial 340B discounts that were intended to ensure low-income access to discounted prescription drugs and services. 
DOWNLOAD PDF
VIEW PDF
FLIP
PDF
How DSH Hospitals Abuse the 340B Drug Pricing Program
FLIP
How DSH Hospitals Abuse the 340B Drug Pricing Program
DOWNLOAD PDF
VIEW PDF
FLIP
PDF
340B Backgrounder
FLIP
In 1992, with the support of the biopharmaceutical industry, Congress created the 340B Drug Pricing Program to help uninsured and vulnerable patients. As part of the law, drug manufacturers provide significant discounts on outpatient medicines and treatments to select eligible health care “covered entities” — often referred to as safety- net providers.
DOWNLOAD PDF
VIEW PDF
FLIP
PDF
Use of Human Cell Lines in Critical Vaccines and Therapies
FLIP
To develop a vaccine that can be produced on a large scale, researchers must grow viruses or bacteria in large quantities and with great consistency.
DOWNLOAD PDF
VIEW PDF
FLIP
PDF
Vaccine Development, Licensure & Safety
FLIP
The creation of a vaccine involves scientists and medical experts from around the world, and it usually requires 10 to 15 years of research before the vaccine is made available to the general public.
DOWNLOAD PDF
VIEW PDF
FLIP
PDF
Value of Vaccines: A Landmark Achievement
FLIP
Vaccination is often cited among the 10 greatest public health achievements of the 20th century. Only access to safe and clean water has had a larger effect on human health by preventing disease and extending lifespans.
DOWNLOAD PDF
VIEW PDF
FLIP
PDF
The U.S. Bioscience Industry Fosters Innovation and Drives America’s Economy Forward
FLIP
The bioscience industry and its supporting ecosystem drive bold innovations to address unmet human needs in the U.S. and around the world, including developing new breakthrough therapies that treat deadly diseases. The collective efforts of the industry and our public and private stakeholders have met the challenges of the COVID pandemic head-on, while lessening the impacts of climate change and nourishing a growing global population.
DOWNLOAD PDF
VIEW PDF
FLIP
PDF
IRA Drug Negotiation: At a Glance
FLIP
Maximum Fair Price: A manufacturer of a drug selected for negotiation will be required to offer a “maximum fair price” for the selected drug with respect to Medicare beneficiaries.
DOWNLOAD PDF
VIEW PDF
FLIP
PDF
Inflation Reduction Act – Medicare Part D Redesign/ Patient Out-Of-Pocket Cap
FLIP
The IRA restructures the Medicare Part D benefit to provide financial protections for beneficiaries and changes the contribution structure for plans, the government, and manufacturers.
DOWNLOAD PDF
VIEW PDF
FLIP
PDF
IRA - Medicare Part D and ‘Smoothing’ of OOP Costs/MPPP
FLIP
Currently, millions of Medicare beneficiaries reach the catastrophic phase in January or February, which exacerbates the financial hardship of the high prices of OOP costs. The Inflation Reduction Act (IRA) will allow Medicare beneficiaries to spread their out-of-pocket cost over the course of the plan year.
DOWNLOAD PDF
VIEW PDF
FLIP
PDF
IRA Medicare Inflation Rebates: At A Glance
FLIP
The Inflation Reduction Act (IRA) of 2022 requires biopharmaceutical companies to pay rebates to the government if the price for drugs in Medicare Part B or Part D increase faster than the rate of inflation.
DOWNLOAD PDF
VIEW PDF
FLIP
PDF
Advanced/Innovative Manufacturing 101
FLIP
Our members are pioneering research into new breakthroughs, but an R&D amortization provision from the '17 Tax Cuts & Jobs Act that just went into effect will negatively impact this work.
DOWNLOAD PDF
VIEW PDF
FLIP
PDF
Advanced/Innovative Manufacturing 101
FLIP
Learn more about Advanced/Innovative Manufacturing and its importance to biotech development.
DOWNLOAD PDF
VIEW PDF
FLIP
PDF
Leveraging V3 for Digitally Derived Endpoints Framework - V3 as Applied to DHTTs Used in Various Drug Development Scenarios
FLIP
Leveraging V3 for Digitally Derived Endpoints Framework - V3 as Applied to DHTTs Used in Various Drug Development Scenarios
DOWNLOAD PDF
VIEW PDF
FLIP
PDF
Private Sector's Critical Role in Biomedical Innovation
FLIP
There is a misguided perception that NIH funding, not private market investment, is largely responsible for the creation and approval of new therapies. A new study by Vital Transformation¹ tests that hypothesis by tracking more than 20,000 patents linked to NIH grant over a 20 year period, identifying those associated with clinical trials and approved medicines, and quantifying the public and private investments made for those investigational and approved medicines.
DOWNLOAD PDF
VIEW PDF
FLIP
PDF
What Are Clinical Trials Like Today?
FLIP
Learn about clinical trials and get answers to your questions.
DOWNLOAD PDF
VIEW PDF
FLIP
PDF
COVID-19 Vaccine Supply Chain: How We Are Vaccinating the Globe
FLIP
To ensure people get safe and effective vaccines as quickly as possible, biotechnology companies have leveraged global partnerships and innovative collaborations to reach patients all around the world.
DOWNLOAD PDF
VIEW PDF
FLIP
PDF
Priority Review Voucher Programs
FLIP
Priority review vouchers provide a powerful incentive to stimulate drug development for underserved diseases or conditions.
DOWNLOAD PDF
VIEW PDF
FLIP
PDF
Food and Drug Administration Expedited Approval Programs
FLIP
The goal of expedited approval pathways is to provide safe and effective therapies for serious, unmet medical needs as quickly as possible.
DOWNLOAD PDF
VIEW PDF
FLIP
Why are seniors paying so much out of pocket for their medicines?
Play
Aug 5, 2019
YouTube
Why are seniors paying so much out of pocket for their medicines?
FLIP
Aug 5, 2019
This whiteboard video helps break down the experience of a senior in the Medicare Part D program.
PLAY VIDEO
FLIP